Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.
Tumor necrosis factor (TNF)-like cytokine (TL1A) is a T-cell costimulator that bolsters cytokine-induced activation through death receptor 3 (DR3). To explore the relationship between T-cell activation and TL1A responsiveness, flow cytometry profiled DR3 expression in resting and activated T cells. In human CD4(+) T cells, DR3 was induced rapidly following activation and expressed prominently by interleukin (IL)-17-secreting T cells (Th17). Splenic T cells from wild-type and DR3-deficient mice showed that TL1A activation of DR3 inhibits Th17 generation (81 ± 2.6% at 100 ng/ml TL1A) from naive T cells. This response was not associated with suppression of T-cell proliferation. Using neutralizing antibodies or T cells derived from genetically modified mice, TL1A inhibition of Th17 development was found to be independent of IL-2, IL-27, γIFN, IFNAR1, and STAT1. Under suboptimal TCR activation, TL1A continued to block IL-17A secretion, however, the reduced threshold of TCR engagement was now linked with an increase in TL1A-driven proliferation. In contrast, fully committed Th17 cells displayed an altered TL1A responsiveness and in the absence of TCR costimulation supported the maintenance of T cell IL-17A expression. Consequently, TL1A orchestrates unique outcomes in naive and effector T-helper cells, which may affect the proliferation, differentiation and maintenance of Th17 cells in peripheral compartments and inflamed tissues.
Jones
Gareth W
GW
Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, Wales, UK.
Stumhofer
Jason S
JS
Foster
Tom
T
Twohig
Jason P
JP
Hertzog
Paul
P
Topley
Nicholas
N
Williams
Anwen S
AS
Hunter
Christopher A
CA
Jenkins
Brendan J
BJ
Wang
Eddie C Y
EC
Jones
Simon A
SA
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D007378:Interleukins / Q000494:pharmacology; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D058504:Th17 Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000494:pharmacology*; D000098546:Interleukin-21
D020381:Interleukin-17; D007376:Interleukin-2; D007378:Interleukins; D053219:Receptors, Tumor Necrosis Factor, Member 25; D016212:Transforming Growth Factor beta; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15; D000098546:Interleukin-21
J Biol Chem. 2003 Oct 3;278(40):39251-8
12882979
J Immunol. 2010 Feb 15;184(4):2130-9
20083667
Nat Immunol. 2005 Nov;6(11):1133-41
16200068
Nat Immunol. 2006 Sep;7(9):937-45
16906166
J Immunol. 1997 Jun 15;158(12):5791-6
9190930
Blood. 2010 Jun 10;115(23):4750-7
20351308
Mol Cell Biol. 2001 May;21(10):3451-61
11313471
Immunity. 2007 Mar;26(3):371-81
17363300
J Exp Med. 2000 Mar 20;191(6):915-26
10727454
Immunity. 2002 Mar;16(3):479-92
11911831
J Immunol. 2004 Jun 1;172(11):7002-7
15153521
Nature. 2006 May 11;441(7090):235-8
16648838
Immunity. 2006 Feb;24(2):179-89
16473830
Immunity. 2008 Jul 18;29(1):79-89
18571443
J Immunol. 2007 Jun 1;178(11):7325-33
17513783
Immunity. 2009 Jan 16;30(1):92-107
19119024
Gastroenterology. 2008 Aug;135(2):552-67
18598698
J Exp Med. 2005 Jan 17;201(2):233-40
15657292
Nat Immunol. 2007 Sep;8(9):967-74
17581537
Nat Immunol. 2006 Sep;7(9):929-36
16906167
J Immunol. 2008 Jun 1;180(11):7102-6
18490707
J Clin Invest. 2008 May;118(5):1680-90
18382764
Nat Immunol. 2007 Dec;8(12):1390-7
17994024
J Exp Med. 2008 May 12;205(5):1049-62
18411337
J Exp Med. 2008 Oct 27;205(11):2457-64
18824582
Biochem J. 2005 Jun 15;388(Pt 3):913-20
15702971
Nat Rev Immunol. 2002 Feb;2(2):116-26
11910893
J Immunol. 2003 Nov 1;171(9):4868-74
14568967
Immunity. 2008 Jan;28(1):29-39
18164222
Nature. 2006 May 11;441(7090):231-4
16648837
Nat Rev Immunol. 2003 Aug;3(8):609-20
12974476
Clin Immunol. 2008 Nov;129(2):249-55
18757243
Trends Immunol. 2006 Jan;27(1):17-23
16290228
J Immunol. 2007 Apr 1;178(7):4033-8
17371957
J Immunol. 2007 Apr 1;178(7):4022-6
17371955
J Exp Med. 2006 Oct 2;203(10):2271-9
16982811
Science. 2007 Jul 13;317(5835):256-60
17569825
Nat Rev Immunol. 2002 Dec;2(12):933-44
12461566
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1116-21
15647361
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8441-6
16698931
Nat Immunol. 2009 Mar;10(3):314-24
19182808
J Immunol. 2004 Oct 15;173(8):5290-7
15470075
J Clin Invest. 2002 Nov;110(10):1503-13
12438448
J Cell Physiol. 2006 Dec;209(3):1021-8
16986165
Curr Opin Immunol. 2006 Dec;18(6):670-5
17010592
Arthritis Rheum. 2006 Mar;54(3):779-87
16508942
Annu Rev Immunol. 2005;23:23-68
15771565
Eur J Immunol. 2007 Jul;37(7):1809-16
17549733
J Immunol. 2007 Dec 1;179(11):7553-60
18025200
Nat Med. 2000 May;6(5):583-8
10802717
Nat Immunol. 2005 Nov;6(11):1123-32
16200070
Cell. 2006 Sep 22;126(6):1121-33
16990136